An investigational GLP-1/GIP/glucagon triple agonist (Lilly) producing the largest weight loss recorded for an anti-obesity drug.
Activates three receptors: GLP-1 and GIP reduce appetite, slow gastric emptying and improve insulin handling, while the added glucagon arm increases resting energy expenditure and hepatic fat mobilisation — lowering intake and raising burn.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
No reviews yet. If you've used Retatrutide, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.